Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making

Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study

Structure and Content of a Taxonomy to Support the Use of Real-World Evidence by Health Technology Assessment Practitioners and Healthcare Decision Makers

Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties, and a Pragmatic Way Forward

The Real-World Evidence Workstream in EUreccA 2025: How the Task Was Addressed

Developing Patient-Centered Real-World Evidence: Emerging Methods Recommendations From a Consensus Process

Enhancing Patient Centricity of Real-World Data Research: An Exploratory Analysis Using the Patient Experience Mapping Toolbox

Use of Structured Template and Reporting Tool for Real-World Evidence for Critical Appraisal of the Quality of Reporting of Real-World Evidence Studies: A Systematic Review

HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force

Assessing Payers’ Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment

How Can We Make More Rapid Progress in the Leveraging of Real-World Evidence by Regulatory Decision Makers?

Cost-Effectiveness of Posthospital Management of Acute Coronary Syndrome: A Real-World Investigation From Italy

Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong?

Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data

Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment

Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact

Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands

Real-World Evidence: Understanding Sources of Variability Through Empirical Analysis

Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative

Use of Real-World Evidence to Support FDA Approval of Oncology Drugs

Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing–Based Tests: Challenges, Opportunities, and Potential Solutions

Developing Markov Models From Real-World Data: A Case Study of Heart Failure Modeling Using Administrative Data

Application of Discrete-Event Simulation in Health Technology Assessment: A Cost-Effectiveness Analysis of Alzheimer's Disease Treatment Using Real-World Evidence in Thailand

Real-World Evidence, Causal Inference, and Machine Learning

Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America

A Real-World Evidence Analysis of Associations Among Costs, Quality of Life, and Disease-Severity Indicators of Alzheimer's Disease in Thailand

Cost-Effectiveness of Cryoballoon Ablation Versus Radiofrequency Ablation for Paroxysmal Atrial Fibrillation in China: Results Based on Real-World Data

Determining the Comparative Value of Pharmaceutical Risk-Sharing Policies in Non–Small Cell Lung Cancer Using Real-World Data

Evolving Use of Real-World Evidence for Devices: Good for Patients, Good for Policy Makers

Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?

Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort

What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews

Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies

Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework

The Use of Decomposition Methods in Real-World Treatment Benefits Evaluation for Patients with Type 2 Diabetes Initiating Different Injectable Therapies: Findings from the INITIATOR Study

Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Making Real-World Evidence More Useful for Decision Making

Cost-Utility Analyses in Diabetes: A Systematic Review and Implications From Real-World Evidence

Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report

Contribute to Value in Health

  • Submit a manuscript/revision
  • Become a peer reviewer
  • Check manuscript status

Scholar One

 

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×